AOD-9604 is a synthetic research peptide derived from the C-terminal region of human growth hormone (HGH). Scientists originally developed this compound to investigate whether certain metabolic activities associated with growth hormone could be studied separately from its effects on physical growth and development.
Unlike full-length human growth hormone, which contains 191 amino acids, AOD-9604 peptide contains just 16 amino acid residues. Its modified structure has made it a subject of scientific research involving lipid metabolism, peptide chemistry, and metabolic signaling.
Early animal studies produced findings that encouraged further investigation. However, larger human clinical trials did not establish a significant weight-loss benefit.
In this article, we explain what AOD-9604 is, its molecular structure, how it may interact with biological pathways, and what scientific research has discovered about this compound.
What Is AOD-9604 Peptide?
AOD-9604 stands for Anti-Obesity Drug 9604. It is a synthetic peptide based on a small fragment of human growth hormone.
The compound contains amino acids corresponding to residues 177–191 of human growth hormone, with an additional tyrosine residue at the N-terminus.
Researchers developed AOD-9604 to investigate whether specific metabolic activities attributed to human growth hormone could be reproduced using a smaller molecular fragment.
Human growth hormone participates in several biological processes, including growth regulation, protein metabolism, and energy balance.
Because the complete hormone affects multiple physiological pathways, researchers became interested in studying smaller structural regions independently.
AOD-9604 emerged from this approach.
Rather than reproducing all the activities of human growth hormone, the peptide was investigated for selected effects on lipid metabolism.
However, AOD-9604 is not the same as human growth hormone, and its clinical effectiveness has not been established.
For a more detailed molecular description, Orion Peptides provides an AOD-9604 technical peptide reference covering its amino acid sequence, structural features, and analytical characteristics.
AOD-9604 Molecular Structure and Chemical Properties
The molecular structure of AOD-9604 is one of its most important characteristics.
It is substantially smaller than full-length human growth hormone and contains a modified amino acid arrangement.
AOD-9604 Chemical Profile
| Property | Description |
|---|---|
| Compound name | AOD-9604 |
| Full name | Anti-Obesity Drug 9604 |
| Classification | Synthetic growth hormone fragment analog |
| Parent molecule | Human growth hormone |
| Amino acids | 16 |
| Molecular formula | C₇₈H₁₂₃N₂₃O₂₃S₂ |
| Molecular weight | Approximately 1,815.1 Da |
| CAS number | 221231-10-3 |
| Amino acid sequence | YLRIVQCRSVEGSCGF |
| Structural characteristic | Intramolecular disulfide bond |
| Research interests | Lipid metabolism, molecular characterization, metabolic signaling |
| FDA status | Not approved |
What Makes the AOD-9604 Structure Different?
AOD-9604 contains several structural features that distinguish it from the parent growth hormone molecule.
1. Short amino acid sequence
Human growth hormone consists of 191 amino acids, while AOD-9604 contains only 16.
This makes AOD-9604 a relatively small peptide fragment analog rather than a complete protein hormone.
2. Additional tyrosine residue
The peptide contains an additional tyrosine residue at its N-terminus.
This modification distinguishes AOD-9604 from the unmodified HGH 177–191 fragment.
3. Disulfide bond
AOD-9604 contains two cysteine residues that form an intramolecular disulfide bridge.
This bond creates a constrained loop within the peptide structure.
The presence of this bridge can influence the molecule’s conformation and its behavior during analytical testing.
These features make AOD-9604 relevant to research involving peptide-fragment chemistry, structural modifications, and the relationship between molecular architecture and biological activity.
How Does AOD-9604 Work?
The AOD-9604 mechanism of action has been investigated primarily through laboratory experiments and animal studies involving lipid metabolism.
Scientists originally wanted to determine whether the C-terminal region of human growth hormone could influence processes associated with fat breakdown and storage.
Several biological pathways became areas of investigation.
1. AOD-9604 and Lipolysis
Lipolysis is the biological process through which stored triglycerides are broken down into fatty acids and glycerol.
This process plays a role in energy metabolism.
Early preclinical research examined whether AOD-9604 could influence lipolysis in animal models.
Some experiments reported changes in lipid metabolism following exposure to the peptide.
These findings suggested that a smaller growth hormone-derived fragment might exhibit selected metabolic activities.
However, experimental findings in animals do not necessarily produce equivalent outcomes in humans.
2. AOD-9604 and Lipogenesis
Lipogenesis involves the synthesis and storage of lipids.
Researchers also investigated whether AOD-9604 affected pathways associated with fat accumulation.
Some early studies reported changes in lipid-related measurements under experimental conditions.
These findings helped explain the original scientific interest in the compound.
Nevertheless, the results do not establish that AOD-9604 produces clinically meaningful reductions in body fat.
3. Beta-Adrenergic Signaling
Beta-adrenergic receptors participate in several physiological processes, including metabolic regulation.
Researchers have investigated whether certain effects observed with AOD-9604 involve beta-adrenergic signaling.
A study published in Endocrinology examined the effects of AOD-9604 and human growth hormone in obese mice, including animals lacking beta-3 adrenergic receptors.
The investigation contributed to understanding possible metabolic pathways associated with the peptide.
However, the primary molecular target of AOD-9604 has not been conclusively established.
For a more detailed discussion of these experimental pathways, read Orion Peptides’ article How AOD-9604 Works: The Science of Targeted Fat Cell Breakdown in Research.
AOD-9604 vs Human Growth Hormone
Although AOD-9604 originates from human growth hormone, these compounds are structurally and biologically different.
| Feature | AOD-9604 | Human Growth Hormone |
|---|---|---|
| Amino acid count | 16 | 191 |
| Molecular classification | Synthetic peptide fragment analog | Protein hormone |
| Structure | Short, disulfide-bridged peptide | Larger folded protein |
| Primary receptor | Not definitively established | Growth hormone receptor |
| Growth-related signaling | Not established as equivalent to HGH | Established biological activity |
| IGF-1 signaling | No established HGH-like systemic activity | Stimulates IGF-1 production |
| Research focus | Peptide chemistry and metabolic pathways | Growth, endocrine regulation, and metabolism |
| FDA status | Not approved | Specific approved prescription compounds exist |
Human growth hormone interacts with the growth hormone receptor and activates biological pathways involved in growth and metabolism.
AOD-9604 was developed to investigate selected effects associated with a much smaller region of the parent hormone.
The important distinction is that sharing part of a hormone’s amino acid sequence does not mean two molecules have identical biological functions.
What Does AOD-9604 Research Show?
Scientific investigations involving AOD-9604 include preclinical studies and human clinical trials.
These different categories of research provide different levels of evidence.
Early Laboratory and Animal Studies
Early investigations focused on the potential metabolic activity of growth hormone fragments.
Researchers examined experimental outcomes involving:
- Lipid metabolism and fat-cell activity.
- Changes in lipid storage.
- Beta-adrenergic signaling.
- Differences between the peptide fragment and full-length human growth hormone.
- Molecular mechanisms associated with metabolic regulation.
Some animal studies reported findings that supported additional investigation.
These results contributed to the development of AOD-9604 as a potential obesity-related drug candidate.
However, preclinical research cannot independently establish clinical effectiveness.
Human Clinical Trials
AOD-9604 eventually progressed into human studies.
One of the most significant was the OPTIONS trial conducted by Metabolic Pharmaceuticals.
The study enrolled 536 adults with obesity, including 502 randomized participants.
Investigators evaluated the effects of AOD-9604 compared with placebo during a structured diet and exercise program.
The study did not demonstrate a statistically significant improvement in weight loss compared with placebo.
Following these findings, the company discontinued its obesity drug-development program in 2007.
This outcome is important because it demonstrates that promising experimental results do not always translate into successful human clinical outcomes.
The FDA has subsequently reviewed evidence concerning AOD-9604, including its chemical properties and available clinical data.
Scientific reference: FDA Scientific Review of AOD-9604.
What Does AOD-9604 Do in Research?
The phrase “what does AOD-9604 do” is frequently associated with questions about its biological activity.
Based on available scientific literature, AOD-9604 has primarily been investigated as a tool for exploring the relationship between growth hormone fragments and metabolic processes.
Its experimental applications can be divided into several areas.
Lipid Metabolism Research
Early investigations examined how AOD-9604 affected lipid-related pathways in experimental models.
The results helped researchers explore possible contributions of the C-terminal growth hormone region to metabolic signaling.
Growth Hormone Fragment Research
AOD-9604 provides an example of how a smaller portion of a protein can be isolated and modified for scientific study.
This approach allows researchers to investigate whether particular regions contribute to specific molecular activities.
Molecular Structure Research
AOD-9604 contains a short amino acid sequence and an intramolecular disulfide bond.
These characteristics make it relevant to studies of peptide conformation, structure, and chemical characterization.
Analytical Peptide Research
Researchers can also investigate methods for identifying and characterizing synthetic peptides using analytical instrumentation.
AOD-9604 provides a defined molecular reference for examining peptide-related analytical measurements.
These research applications should not be confused with established human health benefits.
How Is AOD-9604 Identified in the Laboratory?
Accurate molecular identification is important when studying synthetic peptides.
Two widely used analytical techniques are high-performance liquid chromatography (HPLC) and mass spectrometry.
High-Performance Liquid Chromatography
HPLC separates compounds based on their interactions with a chromatographic system.
It can help researchers evaluate the composition of a peptide sample and detect certain impurities.
For example, an HPLC chromatogram may contain a major peak corresponding to the expected peptide and smaller peaks associated with related substances.
However, a chromatographic purity percentage does not independently prove that a sample contains the correct molecular structure.
Mass Spectrometry
Mass spectrometry measures mass-to-charge ratios of ions.
When combined with appropriate analytical methods, it can provide evidence supporting the molecular identity of a peptide.
For AOD-9604, an observed molecular mass can be compared with the expected mass calculated from its chemical composition.
Additional structural analysis may be necessary to confirm the correct amino acid sequence and disulfide connectivity.
Certificate of Analysis
A Certificate of Analysis, commonly called a COA, documents test results for a particular batch of material.
Depending on the testing program, it may include:
- Compound identification.
- Chromatographic purity.
- Batch identification.
- Quantity or assay results.
- Analytical techniques used.
- Additional quality-control results.
A COA is useful for understanding the reported characteristics of a research sample, but it does not establish therapeutic safety or effectiveness.
AOD-9604 Research Peptide: 5mg vs 10mg
AOD-9604 research materials are available in different labeled quantities.
Orion Peptides lists both 5mg and 10mg versions of AOD-9604 for laboratory research.
| Feature | AOD-9604 5mg | AOD-9604 10mg |
|---|---|---|
| Compound | AOD-9604 | AOD-9604 |
| Labeled quantity | 5mg | 10mg |
| Molecular sequence | Same | Same |
| Compound classification | HGH fragment analog | HGH fragment analog |
| Compound type | Research material | Research material |
| Intended use | Laboratory research only | Laboratory research only |
The difference between these compounds is the nominal quantity of material, not the identity of the peptide.
Researchers reviewing Orion’s available materials can consult the corresponding compound pages:
Both compound pages provide batch-specific analytical information for their listed research materials.
The quantity shown on a research vial is not a clinical dosage recommendation, and research-grade AOD-9604 is not intended for human or veterinary administration.
AOD-9604 Benefits: What Has Actually Been Established?
Searches for AOD-9604 benefits often concern the peptide’s proposed metabolic effects.
It is important to distinguish experimentally investigated mechanisms from demonstrated human benefits.
Early research suggested possible activity involving lipid metabolism and fat-cell signaling.
These findings formed the basis of subsequent clinical investigations.
However, the larger human obesity trial did not establish a statistically significant weight-loss benefit.
Therefore, claims that AOD-9604 reliably improves weight management, accelerates fat loss, or produces specific body-composition outcomes are not supported by convincing clinical evidence.
The compound’s scientific relevance is better understood through its molecular structure and historical role in growth hormone fragment research.
Is AOD-9604 FDA-Approved?
No. AOD-9604 is not approved by the U.S. Food and Drug Administration for weight loss or any other therapeutic indication.
The fact that a compound has been investigated in clinical trials does not mean that it has received regulatory approval.
Similarly, commercially available research-grade AOD-9604 should not be confused with an FDA-approved pharmaceutical compound.
The FDA has examined available information about AOD-9604 in the context of drug compounding, including concerns about its safety and the limitations of clinical evidence.
Research-only labeling does not independently establish that a compound is appropriate for clinical use.
Frequently Asked Questions About AOD-9604
What is AOD-9604 peptide?
AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone. It was developed to investigate metabolic activities associated with a modified growth hormone fragment.
What does AOD-9604 do?
Early experimental studies investigated whether AOD-9604 influenced lipid metabolism, fat-cell activity, and associated biological pathways. These findings do not establish proven therapeutic benefits.
How does AOD-9604 work?
AOD-9604 has been investigated for effects on lipid-related signaling in laboratory and animal models. Its complete molecular mechanism and primary receptor interactions have not been conclusively established.
Is AOD-9604 the same as HGH?
No. HGH is a 191-amino-acid protein hormone. AOD-9604 is a much smaller, modified fragment analog containing 16 amino acids.
How many amino acids are in AOD-9604?
AOD-9604 contains 16 amino acid residues with the sequence YLRIVQCRSVEGSCGF.
What is the molecular weight of AOD-9604?
The molecular weight of AOD-9604 is approximately 1,815.1 daltons.
Does AOD-9604 work for weight loss?
Clinical effectiveness has not been established. A major human trial did not demonstrate a statistically significant improvement in weight loss compared with placebo.
What are the potential benefits of AOD-9604?
Researchers have investigated potential effects on lipid metabolism and metabolic signaling. These remain research findings rather than established clinical benefits.
Is AOD-9604 FDA-approved?
No. AOD-9604 is not FDA-approved for any therapeutic indication.
How is AOD-9604 purity tested?
Laboratories may use HPLC to assess chromatographic purity and mass spectrometry to support molecular identification. Additional testing may be required for comprehensive structural characterization.
What is the difference between AOD-9604 5mg and 10mg?
The primary difference is the labeled quantity of material. Both designations refer to the same AOD-9604 molecular compound.
Conclusion
AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone.
Its modified structure, including an additional N-terminal tyrosine and an intramolecular disulfide bond, distinguishes it from both the unmodified growth hormone fragment and the complete HGH protein.
Early laboratory and animal studies investigated its possible interactions with lipid metabolism and metabolic signaling.
Although these findings encouraged clinical investigation, larger human studies did not establish significant weight-loss efficacy.
Today, AOD-9604 remains an important example in research involving growth hormone fragments, peptide molecular structure, and analytical characterization.
For additional technical information, researchers can consult Orion Peptides’ AOD-9604 molecular reference and its educational article explaining the experimental mechanisms of AOD-9604.
Research Use Disclaimer: This article is intended for scientific and educational purposes only. AOD-9604 is an investigational compound and is not FDA-approved for any therapeutic indication. Research-grade AOD-9604 is not intended for human or veterinary consumption, diagnosis, treatment, or clinical use. The information presented does not constitute medical advice.
Scientific References
- Heffernan MA et al. (2001). The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice. Endocrinology. https://doi.org/10.1210/endo.142.12.8522
- Ng FM et al. (2000). Metabolic Studies of a Synthetic Lipolytic Domain (AOD-9604) of Human Growth Hormone. Hormone Research. PubMed
- U.S. Food and Drug Administration. (2024). AOD-9604 Scientific Review for the Pharmacy Compounding Advisory Committee. FDA Scientific Review
